首页 | 本学科首页   官方微博 | 高级检索  
检索        


Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Authors:Karen Kelly MD  Jeffrey R Infante MD  Matthew H Taylor MD  Manish R Patel MD  Deborah J Wong MD  PhD  Nicholas Iannotti MD  Janice M Mehnert MD  Anja H Loos PhD  Helga Koch PhD  Isabell Speit MD  James L Gulley MD  PhD
Institution:1. Department of Internal Medicine, University of California‐Davis Comprehensive Cancer Center, Sacramento, California;2. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, North Nashville, Tennessee;3. Oregon Health and Science University Knight Cancer Institute, Portland, Oregon;4. Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida;5. Department of Medicine, University of California at Los Angeles, Los Angeles, California;6. Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida;7. Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey;8. Merck KGaA, Darmstadt, Germany;9. Genitourinary Malignancies Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Abstract:
Keywords:avelumab  immunotherapy  JAVELIN  programmed death‐ligand 1 (PD‐L1)  safety
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号